CA3065125C - COMBINATION OF REGORAFENIB AND PD-1/PD-L1 INHIBITORS(2) FOR THE TREATMENT OF CANCER - Google Patents

COMBINATION OF REGORAFENIB AND PD-1/PD-L1 INHIBITORS(2) FOR THE TREATMENT OF CANCER

Info

Publication number
CA3065125C
CA3065125C CA3065125A CA3065125A CA3065125C CA 3065125 C CA3065125 C CA 3065125C CA 3065125 A CA3065125 A CA 3065125A CA 3065125 A CA3065125 A CA 3065125A CA 3065125 C CA3065125 C CA 3065125C
Authority
CA
Canada
Prior art keywords
combination
regorafenib
antibody
inhibitor
limited
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3065125A
Other languages
English (en)
French (fr)
Other versions
CA3065125A1 (en
Inventor
Sabine HOFF
Lars Rose
Dieter Zopf
Fabian Kiessling
Wiltrud LEDERLE
Dennis DOLESCHEL
Original Assignee
Bayer Healthcare LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare LLC filed Critical Bayer Healthcare LLC
Publication of CA3065125A1 publication Critical patent/CA3065125A1/en
Application granted granted Critical
Publication of CA3065125C publication Critical patent/CA3065125C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
CA3065125A 2017-06-02 2018-05-25 COMBINATION OF REGORAFENIB AND PD-1/PD-L1 INHIBITORS(2) FOR THE TREATMENT OF CANCER Active CA3065125C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17174169 2017-06-02
EP17174169.7 2017-06-02
PCT/EP2018/063785 WO2018219807A1 (en) 2017-06-02 2018-05-25 Combination of regorafenib and pd-1/pd-l1(2) inhibitors for treating cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3244313A Division CA3244313A1 (en) 2017-06-02 2018-05-25 Combination of regorafenib and pd-1/pd-l1(2) inhibitors for treating cancer

Publications (2)

Publication Number Publication Date
CA3065125A1 CA3065125A1 (en) 2018-12-06
CA3065125C true CA3065125C (en) 2025-06-10

Family

ID=58992733

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3065125A Active CA3065125C (en) 2017-06-02 2018-05-25 COMBINATION OF REGORAFENIB AND PD-1/PD-L1 INHIBITORS(2) FOR THE TREATMENT OF CANCER
CA3244313A Pending CA3244313A1 (en) 2017-06-02 2018-05-25 Combination of regorafenib and pd-1/pd-l1(2) inhibitors for treating cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3244313A Pending CA3244313A1 (en) 2017-06-02 2018-05-25 Combination of regorafenib and pd-1/pd-l1(2) inhibitors for treating cancer

Country Status (22)

Country Link
US (4) US11951166B2 (enExample)
EP (2) EP4342542A3 (enExample)
JP (3) JP7303122B2 (enExample)
KR (2) KR102843438B1 (enExample)
CN (3) CN110662540B (enExample)
AU (2) AU2018276273B2 (enExample)
BR (1) BR112019025478A8 (enExample)
CA (2) CA3065125C (enExample)
DK (1) DK3630112T3 (enExample)
ES (1) ES2978337T3 (enExample)
FI (1) FI3630112T3 (enExample)
HR (1) HRP20240551T1 (enExample)
HU (1) HUE066487T2 (enExample)
IL (2) IL317015A (enExample)
LT (1) LT3630112T (enExample)
MX (1) MX2023001721A (enExample)
PE (2) PE20242220A1 (enExample)
PL (1) PL3630112T3 (enExample)
PT (1) PT3630112T (enExample)
RS (1) RS65488B9 (enExample)
SI (1) SI3630112T1 (enExample)
WO (1) WO2018219807A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018219807A1 (en) * 2017-06-02 2018-12-06 Bayer Aktiengesellschaft Combination of regorafenib and pd-1/pd-l1(2) inhibitors for treating cancer
CN111001004A (zh) * 2019-10-08 2020-04-14 广州医科大学附属第二医院 一种治疗肝癌的药物组合及其应用
WO2025117638A1 (en) * 2023-12-01 2025-06-05 Yale University Compositions and methods for treating cancer

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ544920A (en) 2003-07-23 2009-11-27 Bayer Healthcare Llc 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide and metabolites for the treatment and prevention of diseases and conditions
KR20080074974A (ko) 2005-11-10 2008-08-13 바이엘 헬스케어 아게 당뇨병성 신경병증을 치료하기 위한 디아릴 우레아
AR062927A1 (es) 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
AR081060A1 (es) 2010-04-15 2012-06-06 Bayer Schering Pharma Ag Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida
UY35006A (es) * 2012-09-06 2014-03-31 Bayer Healthcare Llc Composición farmacéutica recubierta que contiene regorafenib
CA2885688C (en) 2012-09-25 2021-03-02 Bayer Pharma Aktiengesellschaft Combination of regorafenib and acetylsalicylic acid for treating cancer
JP5653489B1 (ja) 2013-07-24 2015-01-14 三菱エンジニアリングプラスチックス株式会社 薄肉光学部材用ポリカーボネート樹脂ペレット及びその製造方法
CN118286440A (zh) 2014-02-04 2024-07-05 辉瑞大药厂 用于治疗癌症的pd-1拮抗剂和vegfr抑制剂的组合
ES2808728T3 (es) 2014-02-21 2021-03-01 Idac Theranostics Inc Agente terapéutico para cáncer sólido
JP6626085B2 (ja) 2014-07-15 2019-12-25 ザ・ジョンズ・ホプキンス・ユニバーシティー 骨髄由来抑制細胞の抑制及び免疫チェックポイント阻害の方法
AR101210A1 (es) * 2014-07-15 2016-11-30 Genentech Inc Métodos de tratamiento de cáncer usando antagonistas de unión al eje pd-1 e inhibidores de mek
CN106794246B (zh) * 2014-08-08 2021-10-15 OncoQuest制药有限公司 肿瘤抗原特异性抗体和tlr3刺激以增强检查点干扰癌症疗法的性能
US20170231929A1 (en) * 2014-08-19 2017-08-17 National University Corporation Okayama University Method for enhancing immune cell function and method for assessing immune cell multifunctionality
AU2015327868A1 (en) 2014-10-03 2017-04-20 Novartis Ag Combination therapies
AU2015346295A1 (en) 2014-11-13 2017-05-25 The Johns Hopkins University Checkpoint blockade and microsatellite instability
WO2016173959A1 (en) * 2015-04-28 2016-11-03 Bayer Pharma Aktiengesellschaft Regorafenib for treating colorectal cancer
WO2017046746A1 (en) 2015-09-15 2017-03-23 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor and a gitr binding molecule, a 4-1bb agonist, or an ox40 agonist
US20190183972A1 (en) 2016-06-03 2019-06-20 Imclone Llc Combination of ramucirumab and pembrolizumab for the treatment of certain cancers
US10251888B2 (en) 2016-06-13 2019-04-09 Chemocentryx, Inc. Method of treating pancreatic cancer
WO2018219807A1 (en) 2017-06-02 2018-12-06 Bayer Aktiengesellschaft Combination of regorafenib and pd-1/pd-l1(2) inhibitors for treating cancer
IL271009B2 (en) * 2017-06-05 2025-10-01 Janssen Biotech Inc Antibodies that specifically bind PD-1 and methods of use

Also Published As

Publication number Publication date
RS65488B9 (sr) 2024-09-30
US11951166B2 (en) 2024-04-09
AU2018276273A1 (en) 2019-12-12
US20200155674A1 (en) 2020-05-21
CN117899212A (zh) 2024-04-19
EP4342542A3 (en) 2024-06-05
BR112019025478A2 (pt) 2020-06-23
RU2019143599A3 (enExample) 2021-09-10
JP7303122B2 (ja) 2023-07-04
LT3630112T (lt) 2024-05-10
CN110662540A (zh) 2020-01-07
US20220133888A1 (en) 2022-05-05
ES2978337T3 (es) 2024-09-10
EP3630112A1 (en) 2020-04-08
RU2019143599A (ru) 2021-07-09
JP2020521786A (ja) 2020-07-27
HUE066487T2 (hu) 2024-08-28
KR20200011971A (ko) 2020-02-04
AU2023282197A1 (en) 2024-01-04
PT3630112T (pt) 2024-04-23
JP7475402B2 (ja) 2024-04-26
IL317015A (en) 2025-01-01
MX2023001721A (es) 2023-02-22
AU2023282197B2 (en) 2025-06-26
IL270948B1 (en) 2025-03-01
KR20240091188A (ko) 2024-06-21
HRP20240551T1 (hr) 2024-07-05
KR102843438B1 (ko) 2025-08-06
DK3630112T3 (da) 2024-04-22
IL270948A (en) 2020-01-30
EP4342542A2 (en) 2024-03-27
EP3630112B9 (en) 2024-06-26
PE20242220A1 (es) 2024-11-19
CA3244313A1 (en) 2025-06-13
US11517622B2 (en) 2022-12-06
RS65488B1 (sr) 2024-05-31
AU2018276273B2 (en) 2023-12-21
US20200188372A1 (en) 2020-06-18
KR102673422B1 (ko) 2024-06-07
EP3630112B1 (en) 2024-01-31
IL270948B2 (en) 2025-07-01
FI3630112T3 (fi) 2024-05-02
BR112019025478A8 (pt) 2022-12-06
US20200179354A1 (en) 2020-06-11
CN117582495A (zh) 2024-02-23
CN110662540B (zh) 2024-01-26
WO2018219807A1 (en) 2018-12-06
PE20200859A1 (es) 2020-08-25
CA3065125A1 (en) 2018-12-06
SI3630112T1 (sl) 2024-06-28
JP2022169780A (ja) 2022-11-09
PL3630112T3 (pl) 2024-07-01
JP2024096905A (ja) 2024-07-17

Similar Documents

Publication Publication Date Title
US10898500B2 (en) Combination of regorafenib and acetylsalicylic acid for treating cancer
AU2023282197A1 (en) Combination of regorafenib and PD-1/PD-L1(2) inhibitors for treating cancer
RU2774838C2 (ru) Комбинация регорафениба и ингибиторов pd-1/pd-l1(2) для лечения рака
HK40015063B (zh) 用於治疗癌症的瑞格菲尼和pd-1/pd-l1(2)抑制剂的组合产品
BR122025015903A2 (pt) Combinação de regorafenib e inibidores de pd-1/pd-l1(2), seu uso, e kit para tratamento de distúrbios hiperproliferativos
HK40015063A (en) Combination of regorafenib and pd-1/pd-l1(2) inhibitors for treating cancer

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20230518

EEER Examination request

Effective date: 20230518

EEER Examination request

Effective date: 20230518

EEER Examination request

Effective date: 20230518

EEER Examination request

Effective date: 20230518

EEER Examination request

Effective date: 20230518

EEER Examination request

Effective date: 20230518

EEER Examination request

Effective date: 20230518

EEER Examination request

Effective date: 20230518

EEER Examination request

Effective date: 20230518

EEER Examination request

Effective date: 20230518

EEER Examination request

Effective date: 20230518